Humphrey B, Fernbach D J, Razek A A, Stuckey W J, Komp D, George S
Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):395-9.
The addition of a single monthy dose of daunorubicin (25 mg/m given intravenously) to the maximum tolerated dose of methotrexate (25 mg/m/dose given orally twice weekly) was evaluated as a maintenance regimen in 0 children with acute lymphoblastic leukemia. Seven patients who were nonevaluable were excluded from the study; 31 patients received methotrexate alone and 32 patients received a combination of methotrezate and daunorubicin. There was no significant difference between the distribution of remission times for the two maintenance regimens (medians of 147 and 162 days, respectively). For patients with only one previous remission, the median length of remission in this study was significantly shorter than that of the original remission time. Despite the known myelosuppressive effects of both agents, daunorubicin did not cause additional toxicity nor did it interfere with the scheduled methotrexate therapy. Although the addition of daunorubicin to methotrexate does not appear to be beneficial in the treatment of acute leukemia, this combination could be evaluated in other cancers in which both agents are known to be effective.
将单剂量柔红霉素（静脉注射25mg/m）添加到甲氨蝶呤最大耐受剂量（每周两次口服，每次25mg/m/剂量）中，作为0例急性淋巴细胞白血病患儿的维持治疗方案进行了评估。7例无法评估的患者被排除在研究之外；31例患者仅接受甲氨蝶呤治疗，32例患者接受甲氨蝶呤和柔红霉素联合治疗。两种维持治疗方案的缓解时间分布无显著差异（中位数分别为147天和162天）。对于仅有一次既往缓解的患者，本研究中的缓解期中位数明显短于初始缓解时间。尽管已知两种药物都有骨髓抑制作用，但柔红霉素并未引起额外毒性，也未干扰预定的甲氨蝶呤治疗。虽然在急性白血病治疗中添加柔红霉素似乎并无益处，但在已知两种药物均有效的其他癌症中可对这种联合用药进行评估。
